It seems that there are a number of things at play here. Its...

It seems that there are a number of things at play here. Its obvious that big bucks had to be spent on a pipeline of technologies for CHM to build the business model it now has... and start bringing some of the tech to Aust to foster our own IP and take advantage of the financial benefits available here for clinical R&D. CHM 2101 is the exception - the multi-trial sites are all in the US (at this stage). The timing of the potential CR ann, IMO, coincided with the CDH17 CAR-T trial start (which was delayed til mid-year) and coincided with the recent cost-cutting measures.

Major funding injection is not likely to happen without cash-burn minimised and the risk of clinical success maximised. CHM 2101 has been described as our lead candidate. To date, all data has been pre-clinical (albeit extremely impressive). So, what would be the most significant data that all financiers would want to see? My guess is clinical data - any early data from a human trial would be what they are after before committing big funds. In CAR-T trials, both toxicity and efficacy can present within less than one month. That could be the de-risking linchpin for serious capitalisation. So, will the market-makers push the SP up in anticipation of the CR to make themselves money in the prelude to such data and a CR or will they suppress the SP to keep the co. hamstrung? The latter, though, only keeps us reliant on Lind Partners, who will happily continue keeping CHM afloat.

What was the underlying motive behind the deliberate forecast of a potential (and very large) placement other than to save on placement costs (as promoted by the co)? Was driving down the SP intentional to allow EVERYONE (including the grumbling retail) to take advantage of the subsequent price suppression? Who is likely to be Mr Market to drive the SP (up or down) ahead of such news? The sophies in the know, the Bell Potters of this world (making a killing in the run up to disclosure or otherwise) of such information before a typical pullback. A lot can happen, share-wise, in a month.